Karo Bio AB Granted 3.8 MSEK From Vinnova
7/1/2014 11:27:56 AM
STOCKHOLM--(BUSINESS WIRE)--Karo Bio AB (publ) (STO:KARO) has been awarded another SEK 3.8 million from Vinnova for the preclinical development of an ERbeta agonist for the treatment of different forms of cancer. In total, Karo Bio has thus been granted SEK 4.8 million for the project from Vinnova.
Help employers find you! Check out all the jobs and post your resume.
comments powered by